Amylyx Pharmaceuticals Inc
NASDAQ:AMLX

Watchlist Manager
Amylyx Pharmaceuticals Inc Logo
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Watchlist
Price: 4.05 USD 2.27% Market Closed
Market Cap: 277.6m USD
Have any thoughts about
Amylyx Pharmaceuticals Inc?
Write Note

Net Margin
Amylyx Pharmaceuticals Inc

-132.1%
Current
-14 933%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-132.1%
=
Net Income
-259.5m
/
Revenue
196.5m

Net Margin Across Competitors

Country US
Market Cap 277.6m USD
Net Margin
-132%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 729.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.6T DKK
Net Margin
35%
Country US
Market Cap 347.8B USD
Net Margin
17%
Country US
Market Cap 248.3B USD
Net Margin
19%
Country CH
Market Cap 197.2B CHF
Net Margin
20%
Country UK
Market Cap 159B GBP
Net Margin
13%
Country CH
Market Cap 169.7B CHF
Net Margin
35%
Country US
Market Cap 149.4B USD
Net Margin
7%
No Stocks Found

Amylyx Pharmaceuticals Inc
Glance View

Market Cap
277.6m USD
Industry
Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2022-01-07. The firm is developing therapies for treatment paradigm for amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive. The firm is pursuing commercialization of its product candidate, AMX0035. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO) also known as ursodoxicoltaurine. AMX0035 is designed to target the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. AMX0035 keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer’s Disease (AD) and multiple sclerosis.

AMLX Intrinsic Value
1.42 USD
Overvaluation 65%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-132.1%
=
Net Income
-259.5m
/
Revenue
196.5m
What is the Net Margin of Amylyx Pharmaceuticals Inc?

Based on Amylyx Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -132.1%.